Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307879 | 0.88 | SLC6A2 (0.51) | SLC6A4SLC6A2ADRB3CYP1A2CYP2C19 | |
| SCHEMBL5312156 | 0.87 | ALOX15 (0.52) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 | |
| SCHEMBL5309985 | 0.86 | ALOX15 (0.57) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 | |
| SCHEMBL5307179 | 0.86 | SLC6A2 (0.54) | SLC6A4SLC6A2ALOX15CYP3A4CYP2D6 | |
| SCHEMBL5307398 | 0.85 | ALOX15 (0.42) | SLC6A4SLC6A2ALOX15ADRB3CYP1A2 | |
| SCHEMBL11393982 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2ADRB3ADRB2ADRB1 | |
| SCHEMBL5304260 | 0.81 | ALOX15 (0.53) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 | |
| SCHEMBL11393725 | 0.81 | ALOX15 (0.53) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 | |
| SCHEMBL11391191 | 0.78 | ALOX15 (0.56) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 | |
| SCHEMBL5304353 | 0.77 | ALOX15 (0.49) | SLC6A4SLC6A2ALOX15CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070198063-A1 | Electrical devices and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| WO-2007041677-A9 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX INC (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041677-A2 | SOFT TISSUE IMPLANTS AND DRUG COMBINATION COMPOSITIONS, AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041584-A2 | IMPLANTABLE SENSORS, IMPLANTABLE PUMPS, AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1675582-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | Warner-Lambert Company LLC (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005025563-A1 | COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND AN SSRI AND/OR SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | ARNERIC STEPHEN P (US) | 2005-03-17 | — | — | US | disclosed |
| US-4271160-A | Substituted morpholine derivatives and pharmaceutical compositions | FARMITALIA CARLO ERBA S.P.A. (IT) | 1981-06-02 | — | — | US | disclosed |
| US-4229449-A | ANTIDEPRESSANTS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1980-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | SLC6A2, SLC18A2, ADRA2C | SLC6A4 4/4885SLC6A2 1/4885ALOX15 2825/4885 |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | SLC6A4 2071/4885SLC6A2 1538/4885ALOX15 217/4885 |
| US-20070196421-A1 | Soft tissue implants and drug combination compositions, and use thereof | COL2A1, MMP1, FN1 | SLC6A4 3009/4885SLC6A2 2691/4885ALOX15 132/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | SLC6A4 2071/4885SLC6A2 1538/4885ALOX15 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.